FY2025 EPS Estimates for Zai Lab Cut by Cantor Fitzgerald

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Free Report) - Analysts at Cantor Fitzgerald reduced their FY2025 EPS estimates for shares of Zai Lab in a research note issued to investors on Tuesday, July 1st. Cantor Fitzgerald analyst L. Watsek now expects that the company will post earnings of ($0.95) per share for the year, down from their prior forecast of ($0.94). Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Zai Lab's current full-year earnings is ($2.58) per share. Cantor Fitzgerald also issued estimates for Zai Lab's FY2026 earnings at $0.30 EPS.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.50) by $0.05. The firm had revenue of $106.49 million during the quarter, compared to analyst estimates of $118.40 million. Zai Lab had a negative net margin of 60.26% and a negative return on equity of 33.35%.

Several other research analysts also recently issued reports on the stock. Wall Street Zen downgraded shares of Zai Lab from a "buy" rating to a "hold" rating in a report on Friday, June 27th. JPMorgan Chase & Co. boosted their price objective on shares of Zai Lab from $44.00 to $51.00 and gave the stock an "overweight" rating in a report on Thursday, March 13th. Leerink Partners set a $75.00 target price on shares of Zai Lab and gave the company an "outperform" rating in a research note on Monday. Finally, Scotiabank began coverage on shares of Zai Lab in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $55.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Zai Lab presently has an average rating of "Moderate Buy" and a consensus target price of $54.28.

Zai Lab Stock Performance

Shares of NASDAQ:ZLAB traded up $0.94 on Thursday, hitting $36.43. 581,960 shares of the company were exchanged, compared to its average volume of 911,726. The company's 50 day moving average price is $33.71 and its two-hundred day moving average price is $31.32. Zai Lab has a one year low of $16.01 and a one year high of $44.34. The firm has a market capitalization of $4.05 billion, a price-to-earnings ratio of -14.63 and a beta of 0.99.

Hedge Funds Weigh In On Zai Lab

Large investors have recently modified their holdings of the stock. Acadian Asset Management LLC acquired a new position in Zai Lab in the first quarter valued at approximately $1,073,000. MPM Bioimpact LLC increased its stake in Zai Lab by 4.2% in the first quarter. MPM Bioimpact LLC now owns 833,659 shares of the company's stock valued at $30,128,000 after purchasing an additional 33,659 shares in the last quarter. Frazier Life Sciences Management L.P. bought a new stake in Zai Lab in the first quarter valued at approximately $12,649,000. Cubist Systematic Strategies LLC increased its stake in Zai Lab by 29.0% in the first quarter. Cubist Systematic Strategies LLC now owns 93,645 shares of the company's stock valued at $3,384,000 after purchasing an additional 21,026 shares in the last quarter. Finally, Royal Bank of Canada increased its stake in Zai Lab by 214.3% in the first quarter. Royal Bank of Canada now owns 13,771 shares of the company's stock valued at $498,000 after purchasing an additional 9,390 shares in the last quarter. 41.65% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Zai Lab

In other news, CEO Ying Du sold 50,000 shares of the company's stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $28.57, for a total transaction of $1,428,500.00. Following the transaction, the chief executive officer directly owned 479,851 shares in the company, valued at approximately $13,709,343.07. This represents a 9.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Yajing Chen sold 9,618 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $30.00, for a total transaction of $288,540.00. Following the transaction, the chief financial officer owned 17,429 shares in the company, valued at $522,870. The trade was a 35.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 160,155 shares of company stock worth $4,959,535. Corporate insiders own 4.96% of the company's stock.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.